Nancy Miller-Rich - 03 May 2021 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Reporting relationship: Director
Issuer ticker: ALDX
Reported as of: 03 May 2021
Net transaction value: +$10,447
SEC form: 4
Accepted by SEC: 21 Oct 2024, 20:22:37 UTC
Next SEC filing: 13 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Nancy Miller-Rich

Key filing fact

Nancy Miller-Rich filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 21 Oct 2024.

Key facts

This page summarizes Nancy Miller-Rich's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 21 Oct 2024, 20:22.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$10,447.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALDX transaction

Common Stock

Purchase

Transaction value: $5,291
Shares: +413
Change %
Price: $12.81
Shares after: 413
Date: 03 May 2021
Ownership: Direct
Footnotes: F1

ALDX transaction

Common Stock

Purchase

Transaction value: $5,156
Shares: +509
Change %: +123%
Price: $10.13
Shares after: 922
Date: 12 Apr 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person. The Reporting Person only recently become aware of these transactions.